The Parexel Podcast | Episode 13: The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19
Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Chief Operating and Growth Officer, talks with Paul Bridges, Head of Consulting, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism. After listening, you can read more about Paul and Sheela’s perspective in this article: https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism
Related Insights
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025